Compare Sana Biotechnology Inc (SANA) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Invesco S&P 500 Momentum ETF trades at $149.66. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPMO | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $161.66 |
52-Week Low | $2.68 | $107.84 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
SPMO trades at $144.50 with a slight 0.42% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights strong momentum performance, with the ETF gaining 7.5% in June 2026 and leading S&P factors. The portfolio is concentrated in technology stocks, benefiting from AI-driven growth but facing volatility risks.
Outlook remains mixed; AI momentum supports growth, but high concentration and bearish technicals pose risks. Investors should weigh the ETF's rules-based strategy against potential sector rotations. Dividend of $0.25 is scheduled for June 2026, adding income appeal amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
